Niraparib tosylate monohydrate chemical name
WebbScottish Medicines Consortium (SMC) decisions For niraparib. SMC No. 1341/18. Niraparib tosylate monohydrate (Zejula®) as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or … WebbPlease note, this OEL/ADE monograph also applies to tosylate monohydrate (CAS RN 1613220-15-7). Niraparib is an orally bioavailable inhibitor of poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and PARP-2), with antineoplastic activity. Niraparib, as tosylate monohydrate, is indicated for the …
Niraparib tosylate monohydrate chemical name
Did you know?
Webb12 apr. 2024 · The FDA approved niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, on March 27, 2024, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary... WebbName Niraparib tosylate monohydrate Drug Entry Niraparib Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor.
Webb1. NAME OF THE MEDICINAL PRODUCT. Zejula 100 mg hard capsules . 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each hard capsule contains niraparib tosylate monohydrate equivalent to 100 mg niraparib. Excipients with known effect . Each hard capsule contains 254.5 mg of lactose monohydrate (see section 4.4). Webb1613220-15-7. Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity [1] [2] [3]. Niraparib (MK-4827) inhibits PARP …
WebbNiraparib hard capsules contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Tartrazine (E 102) This medicinal product contains tartrazine (E 102), which may cause allergic reactions. ADVERSE REACTIONS Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor. The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), … Visa mer Niraparib is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy Visa mer The most common side effects in studies were low blood cell counts, namely thrombocytopenia (in 61% of patients, severe in 29%), anemia (in 50%, severe in 25%) and neutropenia (in 30%, severe in 20%). Other, mostly mild to moderate side effects included Visa mer Mechanism of action Niraparib is an inhibitor of the enzymes PARP1 and PARP2. Pharmacokinetics Visa mer A 2012 study in a cell line found that PARP inhibitors exhibit cytotoxic effects not based solely on their enzymatic inhibition of PARP, but by their trapping of PARP on damaged DNA, and the strength of this trapping activity was ordered niraparib >> olaparib Visa mer No contraindications are listed in the prescribing information. Visa mer No clinical interaction studies have been performed. The potential for interactions with other drugs is low as niraparib and its main metabolite M1 do not significantly interact with any of the important cytochrome P450 liver enzymes in vitro. Niraparib, but not … Visa mer The drug is used in form of the salt niraparib tosylate monohydrate, which is white to off-white, non-hygroscopic crystals. Visa mer
WebbProduct name: Niraparib Tosylate Product Catalogue Number: 206609 Brand: MedKoo Biosciences CAS-No: 1038915-73-9 (tosylate) 1.2 Relevant identified uses of the …
WebbNIRAPARIB TOSYLATE MONOHYDRATE. Molecular Formula C 26 H 30 N 4 O 5 S; Average mass 510.605 Da; Monoisotopic mass 510.193695 Da; ChemSpider ID … admitted solicitorWebb21 juni 2024 · Key facts Decision P/0244/2024: EMA decision of 15 July 2024 on the granting of a product specific waiver for niraparib (tosylate monohydrate) / … admitted to detoxWebbNiraparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib … admitted to collegeWebbNiraparib tosylate monohydrate C26H30N4O5S - PubChem Apologies, we are having some trouble retrieving data from our servers... PUGVIEW FETCH ERROR: 403 Forbidden National Center for Biotechnology Information 8600 Rockville Pike, Bethesda, MD, 20894 USA Contact Policies FOIA HHS Vulnerability Disclosure National Library of Medicine admitted to unionWebb24 apr. 2024 · A process for preparing an enantiomerically enriched (S)-niraparib tosylate monohydrate of Formula (12), comprising: a) contacting a mixture comprising (R)-niraparib tosylate monohydrate and (S)-niraparib tosylate monohydrate with water and a first organic solvent; b) separating (S)-niraparib tosylate monohydrate from the … jr東海 遅延 リアルタイムWebbNiraparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells. How should this medicine be used? Niraparib comes as a capsule to take by mouth once daily. Take niraparib at around the same time every day with or without food. admitting diagnosis amsWebbDuring its meeting of 3 to 5 October 2024, the Committee for Orphan Medicinal Products ( COMP) reviewed the designation EU/3/10/760 for Zejula (niraparib 1) as an orphan medicinal product for the treatment of ovarian cancer. The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for ... admitting and principal diagnosis examples